How to Get Rezdiffra (Resmetirom) in Nevada

What Is Rezdiffra and Why Does It Matter for Nevada Patients?

Rezdiffra (resmetirom) is a thyroid hormone receptor beta (THR-β) selective agonist and the first FDA-approved pharmacotherapy for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (stages F2, F3). The FDA granted accelerated approval on March 14, 2024, based on the MAESTRO-NASH trial published in the New England Journal of Medicine.

Nevada carries a substantial MASH burden. Data from the CDC's National Health and Nutrition Examination Survey estimate that roughly 1.5% to 6.5% of U.S. adults have NASH/MASH, with higher prevalence in populations with obesity and type 2 diabetes. Nevada's adult obesity rate exceeds 30%, placing a disproportionate share of the state's residents in the at-risk population. Before resmetirom, no approved drug existed for MASH, and management relied solely on lifestyle modification and off-label agents.

The MAESTRO-NASH phase 3 trial enrolled 966 adults with biopsy-confirmed NASH and fibrosis stages F1B through F3. At 52 weeks, 25.9% of participants receiving resmetirom 80 mg achieved NASH resolution with no worsening of fibrosis, compared to 9.7% in the placebo arm (P<0.001) [1]. A fibrosis improvement endpoint (at least one stage reduction with no worsening of the NAFLD Activity Score) was met by 24.2% of the 80 mg group versus 14.2% on placebo [1].

Prescriber Eligibility in Nevada

Any Nevada-licensed physician (MD or DO) may prescribe Rezdiffra. Nurse practitioners and physician assistants can also prescribe it, though with different supervisory requirements.

Under Nevada Revised Statutes Chapter 632, advanced practice registered nurses (APRNs) with full prescriptive authority may independently prescribe Schedule II, V and non-scheduled prescription medications. Rezdiffra is a non-controlled substance, so APRNs with prescriptive authority face no additional restriction. Physician assistants operate under a collaborative agreement with a supervising physician per NRS 630.271, and their prescriptive scope covers non-controlled drugs like resmetirom as long as the collaboration agreement permits it.

Hepatologists and gastroenterologists are the most common prescribers, but endocrinologists and primary care physicians who manage MASH patients also initiate therapy. No specialty restriction exists in the Rezdiffra prescribing label. The FDA-approved prescribing information specifies only that the prescriber confirm a diagnosis of MASH with moderate-to-advanced fibrosis before starting treatment [2].

Telehealth Access for Nevada Residents

Nevada permits telehealth prescribing of Rezdiffra. This is a significant access advantage for patients in rural counties.

Nevada's telehealth framework, codified in NRS 629.515, allows licensed providers to prescribe medications during a synchronous audio-video visit without requiring a prior in-person encounter for non-controlled substances. Rezdiffra qualifies. Providers must hold a valid Nevada medical license or be registered through the Interstate Medical Licensure Compact, to which Nevada is a member state.

A typical telehealth workflow for Rezdiffra looks like this:

1. Initial consultation (20 to 30 minutes). The provider reviews medical history, confirms MASH diagnosis, and orders baseline labs.
2. Lab review visit (10 to 15 minutes). Results are discussed and, if appropriate, the prescription is submitted electronically.
3. Follow-up monitoring at 12 weeks, then every 3 to 6 months, depending on fibrosis stage and lab trends.

Patients in Clark County (Las Vegas metro) have numerous in-person specialist options, but the 15 rural counties covering two-thirds of Nevada's land area have limited hepatology access. Telehealth bridges that gap. The American Association for the Study of Liver Diseases (AASLD) practice guidance supports telemedicine for chronic liver disease management when paired with local lab infrastructure [3].

Required Labs Before Starting Rezdiffra

Baseline laboratory testing is non-negotiable before a first dose. The labs serve two purposes: confirming eligibility and establishing monitoring benchmarks.

The minimum panel includes:

• Comprehensive metabolic panel (CMP) with ALT, AST, alkaline phosphatase, albumin, and bilirubin
• FIB-4 index (calculated from age, AST, ALT, and platelet count). A FIB-4 score ≥1.3 warrants further evaluation; scores ≥2.67 suggest advanced fibrosis per the AASLD guidance [3]
• Complete blood count (CBC) to assess platelet count (used in FIB-4 calculation and as an independent fibrosis marker)
• Lipid panel (resmetirom lowers LDL cholesterol and triglycerides as a secondary pharmacologic effect; the MAESTRO-NASH trial documented a 13.6% reduction in LDL at 24 weeks with the 80 mg dose [1])
• Thyroid function tests (TSH and free T4). Because resmetirom is a THR-β agonist, thyroid status should be documented at baseline even though the drug's selectivity for the beta receptor minimizes systemic thyroid effects [2]
• Non-invasive fibrosis assessment. Vibration-controlled transient elastography (FibroScan) or MR elastography is used to stage fibrosis. A liver stiffness measurement of 8.0, 12.0 kPa on FibroScan corresponds roughly to F2, F3, the approved indication range [4]

Several Nevada laboratory networks, including Quest Diagnostics and Labcorp locations in Las Vegas, Reno, Henderson, and Sparks, process all required panels. FibroScan availability is more limited but present at major gastroenterology and hepatology practices in the Las Vegas and Reno metro areas, as well as at select VA Sierra Nevada Health Care System locations.

Monitoring labs (ALT, AST, lipid panel, TSH) are repeated at 12 weeks, then at minimum every 6 months while the patient remains on therapy [2].

Prior Authorization: What Nevada Insurers Require

Most commercial plans and pharmacy benefit managers (PBMs) require prior authorization (PA) for Rezdiffra. The drug's wholesale acquisition cost exceeds $40,000 per year, which places it in a specialty tier on nearly every formulary.

A PA submission for Rezdiffra in Nevada typically requires:

1. Confirmed MASH diagnosis. Documentation can include liver biopsy pathology report, imaging consistent with steatohepatitis, or validated non-invasive test results (FibroScan with elevated CAP and liver stiffness measurement).
2. Fibrosis staging. Evidence of stage F2 or F3 fibrosis. Stage F4 (cirrhosis) falls outside the accelerated approval indication, and most payers deny coverage for F0, F1.
3. Lifestyle intervention documentation. Many PBMs require evidence that the patient has attempted or is concurrently engaged in dietary modification and physical activity counseling for at least 6 months.
4. Lab results. Baseline ALT/AST, FIB-4, and fibrosis imaging within the prior 12 months.
5. Prescriber credentials. Some plans require the prescriber to be a hepatologist or gastroenterologist, or to have documented consultation with one.

The Endocrine Society clinical practice guidelines emphasize that interdisciplinary documentation strengthens PA approvals for metabolic liver disease therapies [5].

Nevada Medicaid does not cover Rezdiffra as of May 2026. The Nevada Department of Health and Human Services Pharmacy and Therapeutics Committee has not added resmetirom to the preferred drug list. Patients on Medicaid who need the drug should discuss manufacturer patient assistance programs (Madrigal Pharmaceuticals offers a copay assistance program for commercially insured patients and a separate patient assistance program for uninsured individuals) or explore 503A compounding alternatives.

Turnaround time for PA decisions in Nevada follows NRS 695G.164, which mandates a response within 3 business days for non-urgent requests and 24 hours for urgent/expedited requests.

Pharmacy Options: Retail, Specialty, and 503A Compounding

Rezdiffra distribution in Nevada occurs through three channels, each with different cost and availability profiles.

Specialty pharmacies handle the majority of Rezdiffra prescriptions nationally. Madrigal Pharmaceuticals uses a limited specialty distribution network. Patients typically receive the drug by mail from a contracted specialty pharmacy. Nevada residents report 5, 10 business day delivery timelines after PA approval.

Retail pharmacies (CVS, Walgreens, independent chains) generally do not stock Rezdiffra due to its specialty classification and high acquisition cost. A prescriber may attempt to route the prescription to a retail pharmacy, but availability is inconsistent.

503A compounding pharmacies in Nevada are licensed by the Nevada State Board of Pharmacy and may compound resmetirom from bulk active pharmaceutical ingredient (API) for individual patient prescriptions. This route is sometimes used when commercial Rezdiffra is inaccessible due to insurance denial or cost. Nevada 503A pharmacies can compound and ship within the state. Federal law under Section 503A of the FD&C Act requires a valid patient-specific prescription and prohibits interstate distribution for 503A entities unless the pharmacy meets specific conditions [6].

Patients pursuing compounding should confirm that the pharmacy holds a current Nevada compounding permit and that the prescriber is willing to write for compounded resmetirom specifically.

Cost and Financial Assistance

The list price for branded Rezdiffra is approximately $47,400 per year at the 80 mg once-daily dose. Out-of-pocket cost varies widely based on insurance.

Madrigal Pharmaceuticals operates two financial programs:

• Commercial copay card. Eligible commercially insured patients may pay as little as $0 per month, with a maximum annual benefit cap (typically $13,000, $15,000).
• Patient assistance program (PAP). Uninsured or underinsured patients with household income at or below 400% of the federal poverty level may qualify for free drug supply.

For patients whose commercial plans deny coverage after PA and appeal, an independent external review is available through the Nevada Division of Insurance. The state mandates that insurers comply with external review decisions under NRS 695G.241 [7].

Dr. Zobair Younossi, chairman of the Global NASH Council and a principal investigator in the MAESTRO-NASH program, noted in a 2024 commentary: "For the first time, we have a drug that addresses the hepatic injury in MASH directly. Access barriers should not prevent eligible patients from receiving it" [8].

What to Expect After Starting Rezdiffra

Resmetirom is taken once daily as an oral tablet, with or without food. The approved dose is 80 mg for patients weighing <100 kg and 100 mg for patients ≥100 kg.

The most common adverse effects reported in MAESTRO-NASH were diarrhea (27.5% vs. 18.4% placebo), nausea (18.9% vs. 13.7%), and abdominal pain [1]. Most gastrointestinal side effects were mild to moderate and resolved within the first 4 to 6 weeks of therapy.

LDL cholesterol reduction is a consistent pharmacologic effect. In the MAESTRO-NASH trial, the 80 mg dose reduced LDL by 13.6% and triglycerides by 18.2% at 24 weeks compared to baseline [1]. Clinicians should account for this when co-managing cardiovascular risk.

Liver enzyme monitoring is required. The FDA label includes a warning about potential hepatotoxicity: ALT and AST should be checked before initiation, every 4 weeks for the first 3 months, then periodically [2]. Treatment should be interrupted if ALT or AST rises above 5 times the upper limit of normal or if clinical signs of liver injury develop.

The AASLD 2023 practice guidance on NAFLD/MASH recommends reassessing fibrosis stage by non-invasive testing at 12 to 24 months on therapy to determine treatment response [3].

Timeline from First Visit to First Dose in Nevada

The total elapsed time from initial provider contact to receiving Rezdiffra depends on the access pathway.

Fastest pathway (telehealth, commercial insurance with PA):

• Week 1: telehealth consultation, labs ordered
• Week 2: lab review visit, prescription submitted, PA initiated
• Week 3: PA approved (average 3, 7 business days in Nevada)
• Week 4, 5: specialty pharmacy ships medication

Slower pathway (Medicaid denial, appeal, or compounding):

• Weeks 1, 3: same as above through PA denial
• Weeks 4, 6: appeal and/or external review
• Weeks 7, 10: transition to compounding pharmacy or PAP enrollment if denial upheld

Rural patients without local FibroScan access may need to add 1 to 2 weeks for travel to a metro imaging center.

Transferring a Rezdiffra Prescription to Nevada

Patients relocating to Nevada from another state can transfer an existing Rezdiffra prescription. Nevada Board of Pharmacy regulations permit inter-state prescription transfers for non-controlled substances. The receiving Nevada pharmacy contacts the originating pharmacy to verify and transfer the prescription electronically.

If the prescribing physician is not licensed in Nevada, the patient must establish care with a Nevada-licensed provider to continue refills. Telehealth makes this straightforward: a single visit to review records and labs is typically sufficient for a new Nevada provider to assume prescribing.

Insurance changes triggered by relocation may reset prior authorization. Patients should contact their new plan's specialty pharmacy team during the transition to avoid gaps in supply.